Forte Biosciences, Inc.(FBRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $18.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
FBRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Forte Biosciences, Inc. (FBRX), a Healthcare sector company. FBRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $18.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Forte Biosciences, Inc. reports net income of $-22.1M, free cash flow of $-18.8M. Top institutional holders of FBRX by reported 13-F value include FEDERATED HERMES,, FRED ALGER MANAGEMENT,, ORBIMED ADVISORS, based on the most recent SEC filings. FBRX trades on the Nasdaq exchange and files with the SEC under CIK 1419041. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Forte Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-22.1M
Free Cash Flow
Q1 2026
$-18.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-95.5% YoYOperating Income
-93.0% YoYEPS (Diluted)
+22.6% YoYTotal Assets
+34.5% YoYOp. Cash Flow
-65.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $36.0K |
| Net Income | $-69.4M -95.5% | $-35.5M -12.7% | $-31.5M -126.8% | $-13.9M +70.1% | $-46.5M -1042.5% | $-4.1M |
| Operating Income | $-70.7M -93.0% | $-36.6M -12.7% | $-32.5M -133.8% | $-13.9M +70.0% | $-46.3M -1038.8% | $-4.1M |
| EPS (Diluted) | $-4.71 +22.6% | $-6.08 +51.2% | $-12.46 -1457.5% | $-0.80 | — | — |
| Total Assets | $82.8M +34.5% | $61.6M +57.9% | $39.0M -7.2% | $42.0M -31.4% | $61.2M +699.7% | $7.7M |
| Operating Cash Flow | $-50.9M -65.5% | $-30.7M -7.1% | $-28.7M -250.7% | $-8.2M +55.6% | $-18.4M -564.9% | $-2.8M |
AI Insight: FBRX Ratio Trends
Data is too sparse to identify reliable trends — only scattered ROE, ROA, and ROIC figures are available, all deeply negative.
• ROE ranged from -45.6% in Q2 2025 to -163.0% in Q1 2025, signaling persistent and volatile net losses.
• ROA was available in only two quarters: -46.5% in Q4 2024 and -72.9% in Q3 2025, both deeply negative.
• OpMargin, NPM, and D/E are entirely absent across all reported periods — fundamental profitability picture is incomplete.
⚠ TTM ROE of -180.2% is the worst reading in the dataset — monitor whether losses are stabilizing or accelerating.
⚠ Absence of D/E data makes leverage assessment impossible; debt levels remain a key unknown for shareholders.
Get alerted when FBRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Forte Biosciences, Inc. including:
Top Institutional Holders of FBRX
FEDERATED HERMES, INC.
$45.7M1,765,516 shFRED ALGER MANAGEMENT, LLC
$33.0M1,273,965 shORBIMED ADVISORS LLC
$31.0M1,196,955 shJANUS HENDERSON GROUP PLC
$30.8M1,188,060 shAffinity Asset Advisors, LLC
$26.2M1,011,890 shMPM BioImpact LLC
$25.9M1,000,682 shADAGE CAPITAL PARTNERS GP, L.L.C.
$24.6M950,000 shVANGUARD CAPITAL MANAGEMENT LLC
$13.8M531,692 shMORGAN STANLEY
$13.0M500,298 shCable Car Capital, LP
$10.4M400,000 sh
| Fund | Value | Shares |
|---|---|---|
| FEDERATED HERMES, INC. | $45.7M | 1,765,516 |
| FRED ALGER MANAGEMENT, LLC | $33.0M | 1,273,965 |
| ORBIMED ADVISORS LLC | $31.0M | 1,196,955 |
| JANUS HENDERSON GROUP PLC | $30.8M | 1,188,060 |
| Affinity Asset Advisors, LLC | $26.2M | 1,011,890 |
| MPM BioImpact LLC | $25.9M | 1,000,682 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $24.6M | 950,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.8M | 531,692 |
| MORGAN STANLEY | $13.0M | 500,298 |
| Cable Car Capital, LP | $10.4M | 400,000 |
More Healthcare Companies
View all Healthcare →Put FBRX on your watchlist
Track score changes the day Forte Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FBRX a good stock to buy?
13F Pro's AI-powered analysis of Forte Biosciences, Inc. (FBRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FBRX are available on the FBRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own FBRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FBRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Forte Biosciences, Inc.'s investment landscape.